KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Depreciation & Amortization (CF) (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 7.1% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, down 8.09% year-over-year, with the annual reading at $16.0 million for FY2025, 8.26% down from the prior year.
  • Depreciation & Amortization (CF) hit $3.7 million in Q4 2025 for Adaptive Biotechnologies, down from $4.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.3 million in Q3 2023 to a low of $2.3 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $4.3 million across 5 years, with a median of $4.6 million in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 129.73% in 2021 and later dropped 22.1% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $4.4 million in 2021, then rose by 9.41% to $4.8 million in 2022, then grew by 1.96% to $4.9 million in 2023, then dropped by 20.28% to $3.9 million in 2024, then dropped by 7.1% to $3.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ADPT at $3.7 million in Q4 2025, $4.0 million in Q3 2025, and $4.1 million in Q2 2025.